Related Experiment Video
Updated: Sep 29, 2025

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
Design and development of photoswitchable DFG-Out RET kinase inhibitors
Yongjin Xu1, Chunxia Gao1, Måns Andreasson1
1Department of Chemistry and Molecular Biology, University of Gothenburg, SE, 41296, Gothenburg, Sweden.
Abstract:
REarranged during Transfection (RET) is a transmembrane receptor tyrosine kinase that is required for development of multiple human tissues, but which is also an important contributor to human cancers. RET activation through rearrangement or point mutations occurs in thyroid and lung cancers. Furthermore, activation of wild type RET is an increasingly recognized mechanism promoting tumor growth and dissemination of a much broader group of cancers. RET is therefore an attractive therapeutic target for small-molecule kinase inhibitors. Non-invasive control of RET signaling with light offers the promise of unveiling its complex spatiotemporal dynamics in vivo. In this work, photoswitchable DFG-out RET kinase inhibitors based on heterocycle-derived azobenzenes were developed, enabling photonic control of RET activity. Based on the binding mode of DFG-out kinase inhibitors and using RET kinase as the test model, we developed a photoswitchable inhibitor with a quinoline "head" constituting the azoheteroarene. This azo compound was further modified by three different strategies to increase the difference in biological activity between the E-isomer and the light enriched Z-isomer. Stilbene-based derivatives were used as model compounds to guide in the selection of substituents that could eventually be introduced to the corresponding azo compounds. The most promising quinoline-based compound showed more than a 15-fold difference in bioactivity between the two isomers in a biochemical assay. However, the same compound showed a decreased Z/E (IC50) ratio in the cellular assay, tentatively assigned to stability issues. The corresponding stilbene compound gave a Z/E (IC50) ratio well above 100, consistent with that measured in the biochemical assay. Ultimately, a 7-azaindole based photoswitchable DFG-out kinase inhibitor was shown to display more than a 10-fold difference in bioactivity between the two isomers, in both a biochemical and a cell-based assay, as well as excellent stability even under reducing conditions.
Insights
Researchers developed light-controllable kinase inhibitors targeting REarranged during Transfection (RET) to study cancer. A stable 7-azaindole inhibitor showed significant differences in activity between isomers in biochemical and cell-based assays.
Area of Science:
- Medicinal Chemistry
- Chemical Biology
- Oncology
Background:
- REarranged during Transfection (RET) is a receptor tyrosine kinase crucial for tissue development and implicated in various human cancers.
- RET activation, through mutations or rearrangements, drives tumor growth and metastasis, making it a key therapeutic target.
- Small-molecule kinase inhibitors offer a therapeutic strategy, but precise control over their activity remains a challenge.
Purpose of the Study:
- To develop photoswitchable DFG-out RET kinase inhibitors for non-invasive, light-based control of RET signaling.
- To investigate the structure-activity relationships of azobenzene-based inhibitors for enhanced light-induced modulation.
- To create inhibitors with significant differences in biological activity between E and Z isomers for precise spatiotemporal control.
Main Methods:
- Design and synthesis of heterocycle-derived azobenzene compounds as photoswitchable RET inhibitors.
- Utilizing quinoline and stilbene scaffolds to guide the development of potent and selective inhibitors.
- Employing biochemical and cell-based assays to evaluate inhibitor efficacy, isomer-specific activity, and stability.
Main Results:
- A quinoline-based inhibitor demonstrated over a 15-fold difference in bioactivity between isomers in biochemical assays, but showed reduced selectivity in cellular assays due to stability issues.
- Stilbene derivatives confirmed the potential for high Z/E activity ratios (>100) in biochemical assays.
- A 7-azaindole based inhibitor achieved >10-fold bioactivity difference between isomers in both biochemical and cell-based assays, exhibiting excellent stability.
Conclusions:
- Photoswitchable DFG-out RET kinase inhibitors can be effectively designed for light-controlled modulation of RET signaling.
- The 7-azaindole scaffold represents a promising platform for developing stable and highly selective photoswitchable kinase inhibitors.
- This approach holds potential for precise spatiotemporal control of RET signaling in cancer research and therapy.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
13:17In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
Related Concept Videos
Inhibition of Cdk Activity
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...